^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

4904 / 15 - Glutamine antagonist DRP-104 enhances anti-tumor responses in KEAP1 mutant lung cancer

Published date:
03/15/2023
Excerpt:
...using an immunocompetent orthotopic lung adenocarcinoma mouse model we find that treatment with DRP-104 increases survival of Keap1 mutant tumor....DRP-104 impairs nucleotide synthesis in KEAP1 mutant tumors and thereby inhibits cancer cell growth...we find that DRP-104 impairs the growth of KEAP1 mutant tumors through both targeting of tumor intrinsic metabolic vulnerabilities and through tumor extrinsic immunostimulatory mechanisms such as promoting the expansion of functional anti-tumor T cell populations.
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Uncovering metabolic bottlenecks in KEAP1 mutant lung Cancer

Published date:
05/28/2020
Excerpt:
Here we show DRP-104 is potent in reducing KEAP1 mutant tumor growth in both murine and patient derived LUAD and squamous tumor models. Our data suggests that DRP-104 is a promising therapy to treat KEAP1 mutant lung cancers and may offer further therapeutic potential when combined with standard of care or other novel metabolic strategies.